Androgenic status in men during COVID-19

BACKGROUND. COVID-19 is a disease that has a negative systemic effect on the human body, including the male gonads. Therefore, the androgenic status in men with COVID-19 needs to be studied.

AIM. To evaluate the levels of total testosterone, sex hormone binding globulin (SHBG) and free testosterone in men in the acute phase of COVID-19 and during convalescence.

MATERIALS AND METHODS. A continuous dynamic prospective study of 70 men with moderate to severe COVID-19 at the age of 50[44; 64] years. During the study, the levels of total testosterone, SHBG were determined with further calculation of the level of free testosterone by Vermeullen. The data were collected twice — at the patient’s hospitalization and at his discharge. The differences between the groups were considered statistically significant at p <0.05.

RESULTS. At the time of hospitalization for COVID-19, hypogonadism syndrome was observed in 61 people — 87%. Patients with hypogonadism did not statistically significant differ in age and severity of COVID-19 disease compared to men without hypogonadism. Inpatient treatment lasting 12[10;14] days resulted in a statistically significant increase in the levels of total testosterone from 4,7[2,96;8,48] to 12,85[8,62;19,2] nmol/l, p<0,001; SHBG from 27,87[20,78;36,57] to 33,76[26,27;52,60] nmol/l, p<0,001 and free testosterone from 107[65;174] to 235[162;337] pmol/l, p<0,001. This led to the elimination of hypogonadism in 28 patients — 40%. Patients with persistent hypogonadism were statistically significantly older than men with normalized testosterone, there were no statistically significant differences in the initial levels of total testosterone, SHBG and free testosterone, and there were also no differences in the prevalence of severe COVID-19 (3,97[2,86;7,46] vs 4,26[2,93;5,96] nmol/l, p=0,100; 28,76[20,78;48,59] vs 24,63[18,85;31,70] nmol/l, р=0,994; 100[58;118] vs 96[64;143] pmol/l, p=0,522; 24 vs 18%, p=0,754, respectively).

CONCLUSION. COVID-19 has a pronounced negative effect on the production of testosterone in men, leading to the development of laboratoric hypogonadism, which is potentially reversible. The reversibility of laboratoric hypogonadism is typical for younger patients.

1. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii. Versiya 11 (07.05.21). Moscow: Ministerstvo zdravookhraneniya RF; 2021. 225 p. (In Russ.).

2. Li X, Zai J, Wang X, Li Y. Potential of large “first generation” human‐to‐human transmission of 2019‐nCoV. J Med Virol. 2020;92(4):448-454. doi: https://doi.org/10.1002/jmv.25693

3. World Health Organization. Infection prevention and control guidance for long-term care facilities in the context of COVID-19: interim guidance, 21 March 2020. World Health Organization; 2020.

4. Wambier CG, Goren A, Vaño‐Galván S, et al. Androgen sensitivity gateway to COVID‐19 disease severity. Drug Dev Res. 2020;81(7):771-776. doi: https://doi.org/10.1002/ddr.21688

5. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31(8):1040-1045. doi: https://doi.org/10.1016/j.annonc.2020.04.479

6. Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020;83(1):308-309. doi: https://doi.org/10.1016/j.jaad.2020.04.032

7. Wambier CG, Goren A, Ossimetha A, et al. Androgen-driven COVID-19 Pandemic Theory. Preprint. 2020. doi: https://doi.org/10.13140/RG.2.2.21254.11848

8. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign.” J Am Acad Dermatol. 2020;83(2):680-682. doi: https://doi.org/10.1016/j.jaad.2020.05.079

9. Rastrelli G, Di Stasi V, Inglese F, et al. Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients. Andrology. 2021;9(1):88-98. doi: https://doi.org/10.1111/andr.12821

10. Kamalov AA, Mareev VYu, Orlova YaA, et al. Features of a new corOnavirUs infection course and optioNs therapy DEpending on the andRogenic status (FOUNDER): androgenic status in men with COVID-19 and its relationship with the disease severity. Urologiya. 2021;6:85-99 (In Russ.). doi: https://doi.org/10.18565/urology.2021.6.85-99

11. Moreno‐Perez O, Merino E, Alfayate R, et al. Male pituitary–gonadal axis dysfunction in post‐acute COVID‐19 syndrome—Prevalence and associated factors: A Mediterranean case series. Clin Endocrinol (Oxf). 2022;96(3):353-362. doi: https://doi.org/10.1111/cen.14537

12. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672. doi: https://doi.org/10.1210/jcem.84.10.6079. PMID: 10523012.

13. Dedov II, Mel’nichenko GA, Rozhivanov RV, Kurbatov DG. The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project. Problems of Endocrinology. 2015;61(5):60-71. (In Russ.). doi: https://doi.org/10.14341/probl201561560-71

14. Dedov II, Melnichenko GA, Rozhivanov RV, Kurbatov DG. Guidelines for the Diagnosis and Treatment of testosterone deficiency (hypogonadism) in male patients. Problems of Endocrinology. 2016;62(6):78-80. (In Russ.). doi: https://doi.org/10.14341/probl201662678-80

15. STATISTICA help [Internet], 2019. STATISTICA automated neuronal networks overviews — network types. The multilayer perceptron neural networks. [cited 2019 Apr 11] Available from: http://documentation.statsoft.com/STATISTICAHelp.aspx?path=SANN/Overview/SANNNeuralNetworksAnOverview

16. Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513

17. Agarwal P, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21(1):64-70. doi: https://doi.org/10.4103/2230-8210.196008

18. Kumar M, Dutta D, Anne B, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes, Metab Syndr Obes Targets Ther. 2014;21(1):481-486. doi: https://doi.org/10.2147/DMSO.S50777

19. Cheung KKT, Luk AOY, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig. 2015;6(2):112-123. doi: https://doi.org/10.1111/jdi.12288

20. Mel’nichenko GA, Shestakova MV, Rozhivanov RV. The clinical and epidemiological characteristics of hypogonadism in men with type 2 diabetes mellitus. Diabetes mellitus. 2020;22(6):536-541. (In Russ.). doi: https://doi.org/10.14341/DM10211

21. Rozhivanov RV, Essaoulenko DI, Kalinchenko SY. The prevalence of hypogonadism in patients with diabetes mellitus type 2 (DMT2). The Aging Male. 2006;9(1):27.

22. Vertkin AL, Morgunov LIu, Shakhmanaev KhA. Gipogonadizm i khronicheskaia obstruktivnaia bolezn’ legkikh. Urologiia. 2013;5:116-123. (In Russ.).

23. Das L, Dutta P, Walia R, et al. Spectrum of Endocrine Dysfunction and Association With Disease Severity in Patients With COVID-19: Insights From a Cross-Sectional, Observational Study. Front Endocrinol (Lausanne). 2021;12:645787. doi: https://doi.org/10.3389/fendo.2021.645787